WilliamIraBensingerMD

Oncology • Lakewood, WA

Associate Professor of Medicine, University Wash

Join to view full profile

Are you Dr. Bensinger?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 59 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
11311 Bridgeport Way SW Ste 302
Lakewood, WA 98499
Phone+1 253-533-6700

Fax+1 253-584-1271

Summary

Dr. William Bensinger, MD is an oncologist in Lakewood, Washington. He is currently licensed to practice medicine in Washington and Alaska. He is affiliated with Swedish First Hill Campus and is an Associate Professor of Medicine at University Wash.

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1973 - 1974
Northwestern University The Feinberg School of MedicineClass of 1973

Certifications & Licensure

WA State Medical License 1976 - 2025
AK State Medical License 2021 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 1997 Nov 01
Completed
Phase 2
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 1997 Dec 01
Completed
Phase 2
Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 1999 Jun 01
Completed
Phase 1, Phase 2
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 2000 Aug 01
Completed
Phase 3
Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma Start of enrollment: 2003 Jul 01
Completed
Not Applicable
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Start of enrollment: 2005 Jul 01
Completed
Phase 3
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 1, Phase 2
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma Start of enrollment: 2005 Sep 01
Completed
Phase 2
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma Start of enrollment: 2005 Nov 01
Completed
Phase 2
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2006 Aug 01
Unknown status
Phase 2
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2010 Jun 01
Terminated
Not Applicable
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jul 23
Completed
Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Gary J Schiller, Brea C Lipe, Nizar J Bahlis, Sascha A Tuchman, William I Bensinger
Clinical Lymphoma, Myeloma & Leukemia. 2023-09-01
10 citations
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander
Ejhaem. 2022-11-01
9 citations
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke
Leukemia & Lymphoma. 2022-10-01

Press Mentions

Trials Investigate Novel Agents, Autologous Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaJune 4th, 2016

Grant Support

Targeted Radiotherapy With 90y-Bc8 Monclonal Antibody, Fludarabine And TBI FollowNational Cancer Institute2011
Autologous Morrow TransplantationNational Cancer Institute1996
In Vitro Detection Of Residual LeukemiaNational Cancer Institute1989–1991
Autologous Marrow Transplantation For Multiple MyelemalNational Cancer Institute1989–1991
Transfusion Support--CoreNational Cancer Institute1987–1991
Platelet Alloimmunity In Marrow TransplantationNational Cancer Institute1987–1991